Mugglehead reveals a number of stocks set to take advantage of hemp

CBJ Newsmakers

VANCOUVER, British Columbia, Jan. 17, 2019 (GLOBE NEWSWIRE) — Hemp. It’s one of the world’s fastest growing plants—a separate species of the cannabis sativa genus that, due to its >0.3% tetrahydrocannabinol (THC) content, makes it literally almost impossible to get high from smoking it.

But that’s not stopping it from taking the marijuana industry by storm.

Just weeks ago, U.S. President Trump signed the 2018 Farm Bill into law. The newly revamped bill legalizes industrial hemp in the U.S., and in doing so not only makes hemp and CBD eligible for lucrative federal crop insurance, but also removes CBD from the Controlled Substances Act.

CBD, or cannabidiol, is the naturally occurring phytocannabinoid in the hemp plant that studies suggest can be used to treat inflammation, pain, anxiety, depression, and a plethora of other health conditions—all without the psychoactive effect found in marijuana.

The updated 2018 Farm Bill is a major step forward in the marijuana industry’s quest for legitimacy, as the still-nascent sector wrestles with lower than expected earnings and explosive short-seller claims.

However, challenges remain ahead for the U.S. hemp-derived CBD market. Despite the Farm Bill legalizing industrial hemp at the federal level, individual states still have the final say in the legislation surrounding hemp legality. Moreover, even though CBD has been removed from the Controlled Substances Act, the FDA remains the supreme arbiter of whether or not CBD is allowed to be in food and wellness products.

Despite these challenges, companies across the United States are gearing up for CBD’s anticipated legalization—from pharmaceutical firms to industrial hemp farms and more.

CBD Legitimacy Through Pharmaceutical Support

The U.S. Food and Drug Administration’s (FDA) primary mandate is to protect public health by ensuring the safety and efficacy of drugs, biological products, and medical devices.

With this in mind, it’s easy to see just how important scientific evidence will be in the rollout of hemp-derived CBD products across the United States.

British biopharmaceutical company GW Pharmaceuticals PLC (NASDAQ: GWPH), a pioneering authority in plant-derived cannabinoid therapeutics, is providing much needed evidence for CBD-based medicines in droves. Just recently, the company’s CEO spoke at the JP Morgan HealthCare Conference — one of the largest healthcare investment conferences in the world.

GW Pharmaceuticals is the company behind Epidiolex, an FDA approved drug that contains purified CBD and is used to treat a rare epilepsy syndrome in children known as Lennox-Gastaut syndrome or Dravet syndrome. It’s also the first cannabis-related company to receive analyst coverage from J.P. Morgan. That should come as little surprise, since Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, J.P. Morgan and Cowen and Company, LLC all acted as joint book-running managers for their most recent offering of nearly US$350 million.

With that type of coverage and investment services from some of the biggest banks in the world, further support from the scientific community is all but guaranteed at this point, and will likely serve as a catalyst in building momentum towards broader FDA approved CBD products.

In the meantime, other well-funded firms are getting ready for a tidal wave of CBD demand…

The U.S. Hemp Farm Rush, A Prelude To CBD-Infused Beverages

The world’s biggest marijuana companies, both Canadian and American, are already preparing to capitalize on hemp-derived CBD market through the development of expansive industrial hemp farm projects in the U.S.

Canopy Growth Corporation (NYSE: CGC) (TSE: WEED) is a prime example of a Canadian foray into the U.S. industrial hemp market, having recently announced plans to invest up to US $150 million in the development of large-scale production capabilities for hemp extraction and product manufacturing in the Southern Tier of New York.

It’s a logical move—especially considering the “lucrative” U.S. federal crop insurance subsidies we mentioned earlier.

Via Market Watch:

“Over the new farm bill’s five-year life, the Congressional Budget Office estimates that annual subsidies totaling between $7.5 and $8.5 billion will flow to crop producers and the insurance industry.”

Canopy Growth is competing against the reigning hemp-derived CBD producer, Colorado-based Charlottes Web Holdings, Inc. (CSE: CWEB) (OTC: CWBHF) — a vertically integrated producer of premium CBD wellness products who touts 300 acres of hemp planted as of 2018.

Charlotte’s Web is of particular interest, not only for their current dominance of the American hemp-derived CBD market, but because they recently hired Eugenio Mendez as their Chief Growth Officer.

Mr. Mendez previously served as Vice-President, Global Marketing of Water, Enhanced Water and Sport Drinks for Coca-Cola.

Could Charlotte’s Web be gearing up for an infused CBD beverage division?

The message is clear: CBD-infused beverages are poised to become one of the marijuana sectors next biggest growth segments, and cannabis companies know it.

It’s why Tilray (NASDAQ: TLRY) entered into a research partnership with Budweiser brewer Anheuser-Bush InBEV SA, an agreement in which both companies are able to invest up to US $50 million towards the research of non-alcoholic THC and CBD beverages.

The message, however, is nothing new. Investments from major alcohol companies into the cannabis sector have been fueling speculation over the direction of the CBD-infused beverage market for months.

Via Bloomberg:

“AB InBev is the third alcohol company to partner or invest in a Canadian marijuana producer after [Canada] became the first major economy to legalize marijuana in October.

Molson Coors Brewing Co. signed a joint venture with Hexo Corp., while Constellation Brands Inc. is now the biggest shareholder in Canopy Growth Corp . . .”

But while the number of major beverage companies beginning to enter the CBD-infused beverage space is increasing, a handful of companies have already set the stage to take advantage of hemp’s legalization.

The Alkaline Water Company (NASDAQ: WTER) (TSXV: WTER), a leading producer of premium bottled alkaline drinking water sold under the brand name Alkaline88®, is one of these such companies. 

The Alkaline Water Company, which plans to launch their CBD-infused alkaline water product line sometime in Q1 2019, has already achieved a national presence in all 50 U.S. States, selling their products in over 47,500 locations with a distribution that spans more than 150,000 stores through the biggest national grocery retailers such as Walmart, Kroger, Safeway-Albertsons and CVS.

Alkaline Water’s leading brand, Alkaline88®, is not only the #1 selling bulk alkaline water in the U.S, but it’s the fastest growing premium water brand in the U.S.

And unlike many of the companies touting a CBD-infused beverage line to excite the market, the Alkaline Water Company has already been researching the infused space and has been taste-profiling and testing product formulations for the launch of their new product line.

It’s already announced a co-packing agreement with American Nutritional Products Inc. (ANP) for the development of each of its recently announced hemp product extensions.

But that’s not all.

The First National U.S. Beverage of its Kind

One of the biggest challenges when it comes to infusing beverages with CBD, or hemp, is maintaining efficacy.

But Alkaline Water Company has already secured a deal that brings a patent-pending process that can bring true water-soluble, full-spectrum features of bioactive natural hemp extract molecules to U.S. consumers.

According to the Alkaline Water Company:

“The Alkaline Water Company Inc. has entered into a Binding Letter of Agreement with Infusion Biosciences, Inc., that provides a non-exclusive license to utilize its proprietary Aqueous Phytorecovery Process (“APP”) technology.

Under the Agreement, IBS agreed to provide A88 Infused with ready-to-drink natural hemp-extract formulations.”

With APP’s formulations, A88 Infused is expected to be the first national U.S. beverage company to bring true water-soluble, full-spectrum features of bioactive natural hemp extract molecules to U.S. consumers.

The Alkaline Water Company could very well be one of the first U.S. beverage companies to bring CBD-infused beverages to the market with distribution — creating a first-mover brand advantage for CBD-infused drinks that could potentially rival the likes of Canopy Growth, Tilray, and others…

The Year Of CBD-Infused Drinks

Though the passing of the 2018 Farm Bill was a watershed moment for the hemp-derived CBD market, state specific legislation on industrial hemp production remains a potential stumbling block for would-be farmers. As this legislation is ironed out throughout the year and the reality of CBD-infused beverages draws nearer, expect behemoth beverage companies to be caught off-guard by smaller, more nimble drink companies — like The Alkaline Water Company.

The original post can be found here:

Directors of Mugglehead own shares of Alkaline Water (WTER) at the time of this writing.

About Mugglehead is a digital publisher dedicated to cannabis news, investments, culture, and science, owned by Mugglehead Media Corp. We publish original content, including video, interviews and articles. Because many of the companies and trends we cover are related to investments and stocks within the cannabis industry, please review our disclaimer and forward-looking statements below.

Original content created by Mugglehead Media Corp. © 2019 is protected by copyright laws.

We have lots in store for 2019 so be sure to check us out!

Visit us at daily for all things cannabis-related.



Disclaimer and Forward-Looking Statements

Mugglehead Media Corp. and (collectively, Mugglehead) is a news and media publisher dedicated to cannabis. It is not registered as an investment adviser, broker-dealer or other financial or securities professional with any financial or securities regulatory authority. You understand that no content published by Mugglehead constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Mugglehead does not render general or specific investment advice and does not endorse or recommend the business, products, services or securities of any industry or company mentioned on this Site.

It is not intended to provide tax, legal, insurance or investment advice, and nothing on the Site should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation to buy or sell any security. None of the content we publish is provided with a view to inviting, inducing or encouraging any person to make any kind of investment decision. You are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should consult an attorney or tax professional regarding your specific legal or tax situation. You should also consult a licensed professional, such as a financial advisor or broker-dealer, when dealing in any securities or making any investment decisions. We do not guarantee that any of the companies mentioned on or any of our newsletters or content will perform as we expect, and any comparisons we have made to other companies may not be valid or come into effect.

This news release is not an offer to sell or a solicitation of an offer to buy any securities or commodities. To the extent that anything in this press release may be deemed to be investment advice or a recommendation in connection with a particular company or security, such information is impersonal and is not tailored to the needs of any specific person.

You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Site will not contain a list or description of relevant risk factors. In addition, some of the securities about which content is published by us have a low market capitalization, insufficient public float and/or are thinly traded. Such securities are subject to more risk than securities of larger companies, including greater volatility, lower liquidity and less publicly available information. Content we publish may have an effect on the price of such securities.

From time to time, Mugglehead (on behalf of itself and any partner, director, officer or insider of Mugglehead) may have a financial or other interest in the party or parties featured on the Site, within the meaning of National Instrument 31-103 – Registration Requirements, Exemptions, and Ongoing Registrant Obligations, published by the Canadian Securities Administrators, as a result of ownership of securities in, compensation received or receivable from or other financial arrangement with such party or parties featured in this press release. We will disclose if we have a position in any such party or parties, as at the date of publication of this press release; however, we may not update this disclosure after such date. Directors of Mugglehead own shares of Alkaline Water (WTER) at the time of this writing.

In addition to historical information, this press release may contain forward-looking statements, including statements with respect to third parties regarding product plans, future growth, market opportunities, strategic initiatives, industry positioning, customer acquisition, the amount of recurring revenue and revenue growth. In addition, when used on the Site, the words ”will,” ”expects,” ”could,” ”would,” ”may,” ”anticipates,” ”intends,” ”plans,” ”believes,” ”seeks,” ”targets,” ”estimates,” ”looks for,” ”looks to,” ”continues” and similar expressions, as well as statements regarding a third party’s focus for the future, are generally intended to identify forward-looking statements. Each of the forward-looking statements we make in this press release involves risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those disclosed by the companies featured in this release in their public securities filings. You should carefully review the risks described therein. You should not place undue reliance on these forward-looking statements, which speak only as of the date such statement was published. Mugglehead undertakes no obligation to publicly release any updates or revisions to the forward-looking statements or reflect events or circumstances after the date of their publication, except as required by law.

From time to time, reference may be made in this press release to prior articles or opinions we have published. These references may be selective, may reference only a portion of an article or opinion, and are likely not to be current. As market information changes continuously, previously published information and data, and any references thereto, may not be current and should not be relied upon.

If you ever have any questions or concerns about our business or publications, we encourage you to contact us.

CONTACT: Contact: